Exciting News from Perimeter Medical Imaging AI, Inc.
The Solution to High Reoperation Rates in Breast-Conserving Surgeries
Perimeter OCT B-Series is revolutionizing the field of margin assessment in breast-conserving surgeries by combining AI technology with optical coherence tomography. This innovative approach aims to tackle the unacceptably high reoperation rates associated with BCS, as highlighted in a recent study published in the Annals of Surgical Oncology. The study revealed reoperation rates of 21.1% among commercially insured women and 14.9% among the Medicare cohort, emphasizing the urgent need for a more effective solution.
Key Milestones and Expectations
The primary endpoint results from the OCT B-Series pivotal trial are expected in Q4-2024, with the potential to support submission to the FDA in 2025. This could mark a significant milestone for Perimeter by securing the first-ever marketing clearance for specific use in breast tissue, breast cancer, and margin evaluation. It would represent a major inflection point for the company’s business and could have a transformative impact on the field of breast cancer surgery.
Toronto and Dallas, Oct. 1, 2024 /PRNewswire/ – Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (“Perimeter” or the “Company”) announced the completion of patient enrollment in a pivotal study evaluating the use of its next-generation Perimeter B-Series OCT system during breast-conserving surgeries. The combination of AI technology and OCT holds the promise of reducing reoperations and improving patient outcomes in the future.
Impact on Individuals
For individuals facing breast-conserving surgery, the introduction of the Perimeter OCT B-Series system could offer hope for a more accurate and efficient procedure. By reducing the need for reoperations, patients may experience a smoother recovery process and better long-term outcomes. The innovative technology has the potential to alleviate the stress and uncertainty associated with margin assessment, providing peace of mind for both patients and healthcare providers.
Global Implications
On a global scale, the development of the Perimeter OCT B-Series system could have far-reaching implications for breast cancer treatment. By improving the accuracy of margin assessment and reducing reoperation rates, this technology has the potential to standardize care practices and enhance surgical outcomes worldwide. The impact of this innovation could be felt across healthcare systems, leading to more efficient and effective breast cancer treatments for patients everywhere.
Conclusion
In conclusion, the Perimeter OCT B-Series system represents a groundbreaking advancement in the field of margin assessment for breast-conserving surgeries. By combining AI technology with optical coherence tomography, Perimeter Medical Imaging AI, Inc. is paving the way for improved patient outcomes and reduced reoperation rates. The completion of patient enrollment in the pivotal study marks a significant step towards potentially obtaining FDA approval and transforming the landscape of breast cancer surgery. With this innovative technology on the horizon, the future looks brighter for individuals facing breast cancer and the healthcare community at large.
